Mereo BioPharma Group (MREO) Expected to Release Quarterly Earnings on Tuesday

Posted by Francis Steltz on Aug 4th, 2026

Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) will likely be posting its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Mereo BioPharma Group to post earnings of ($0.01) per share and revenue of $3.50 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 2:00 AM ET.

Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.03). On average, analysts expect Mereo BioPharma Group to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Mereo BioPharma Group Trading Up 3.3%

Shares of MREO stock traded up $0.01 on Tuesday, reaching $0.33. 142,618 shares of the stock were exchanged, compared to its average volume of 5,323,200. Mereo BioPharma Group has a twelve month low of $0.20 and a twelve month high of $2.37. The company has a market capitalization of $52.04 million, a price-to-earnings ratio of -6.52 and a beta of 0.36. The business’s 50 day moving average price is $0.32 and its 200 day moving average price is $0.35.

Institutional Investors Weigh In On Mereo BioPharma Group

Several hedge funds have recently made changes to their positions in MREO. Marex Group plc acquired a new position in Mereo BioPharma Group in the 2nd quarter valued at about $27,000. Virtu Financial LLC purchased a new position in shares of Mereo BioPharma Group in the 3rd quarter valued at approximately $33,000. Squarepoint Ops LLC increased its holdings in shares of Mereo BioPharma Group by 45.4% in the third quarter. Squarepoint Ops LLC now owns 30,055 shares of the company’s stock valued at $62,000 after purchasing an additional 9,387 shares during the period. Aquatic Capital Management LLC increased its holdings in shares of Mereo BioPharma Group by 99.5% in the third quarter. Aquatic Capital Management LLC now owns 53,712 shares of the company’s stock valued at $111,000 after purchasing an additional 26,782 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Mereo BioPharma Group during the second quarter worth approximately $188,000. Institutional investors and hedge funds own 62.83% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MREO. BTIG Research reissued a “buy” rating and set a $1.00 target price on shares of Mereo BioPharma Group in a research report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mereo BioPharma Group in a report on Thursday, July 2nd. Finally, Zacks Research upgraded shares of Mereo BioPharma Group from a “strong sell” rating to a “hold” rating in a research note on Wednesday, June 10th. Three analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $3.25.

View Our Latest Report on MREO

Mereo BioPharma Group Company Profile

(Get Free Report)

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.